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Cancer in children is rare. In industrialized countries, only 0.5-1 % of all cancers occur in 
children below the age of 15 years [1]. The annual incidence in Europe was 139 per million 
children for the period 1988-1997 [2]; in Norway, approximately 160 children develop cancer 
each year [3]. The overall chance to survive childhood cancer has increased substantially 
during the last decades, from 54 % for cases diagnosed between 1978-1982, to 75 % for those 
diagnosed 1993-1997 [4]. Highest survival rates in Europe are reported from Western Europe 
and the Nordic countries [5, 6].    
In contrast to adult cancer, which comprises mainly carcinomas in the respiratory, 
gastrointestinal and reproductive organs, cancer in children is rarely manifested in these 
localizations. In addition, the histopathology of pediatric malignancies is remarkably different 
and mainly characterized by immature or embryonal cells from different developmental 
stages – rapidly proliferating and embarrassed to mature [7]. 
Leukemia is the most common pediatric cancer (35-45 % of cancer cases), followed by 
tumors of the central nervous system (around 30 %). The majority of other cases belong to the 
groups of lymphomas, sarcomas, or embryonal tumors like nephroblastoma, hepatoblastoma, 
and neuroblastoma [1].    
2.1 Neuroblastoma 
With an annual incidence of 7-12 new cases per million children [1, 8, 9], neuroblastoma is 
the most frequently diagnosed extra-cranial solid tumor in childhood, accounting for 7-8 % of 
all pediatric malignancies and 15 % of childhood cancer deaths [10, 11]. For patients with 
high-risk tumors, long-term survival rates are still below 40 %, making treatment of 
neuroblastoma to one of the major challenges in pediatric oncology [12-14].  
Neuroblastoma comprises a group of biologically distinct tumors with extremely 
heterogeneous behavior. On the one hand, localized tumors, which are often asymptomatic, 
but even metastasized neuroblastomas in infants can regress completely or differentiate 
spontaneously into benign histological variants without any treatment at all [15-17]. On the 
other hand, metastatic neuroblastomas in children older than 18 months at diagnosis cause 
severe systemic illness and are associated with poor prognosis, despite all modern and 
aggressive multi-modal treatment efforts [18].  
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In 2003, Garrett Brodeur addressed the “enigmatic” nature of neuroblastoma in a state-of-the-
art review and noted that “few tumors have engendered as much fascination and frustration 
for clinical and laboratory investigators as neuroblastoma” [19]. One way to improve 
treatment and hopefully increase survival is to unravel the molecular basis of neuroblastoma 
tumorigenesis. The identification of genes and their regulators, like miRNAs and signaling 
pathways, responsible for the malignant transformation of neuroblastoma cells, will help to 
define patient risk groups on a molecular basis [20-23] and aid to develop new therapeutic 
strategies based on directly targeting these biological pathways [14, 24]. 
2.1.1 Neuroblastoma – a disorder of normal development 
Neuroblastoma belongs to the group of embryonal tumors, neoplasms in which the cell of 
origin physiologically participates in the organogenesis during embryonal development. 
Normal development is characterized by precisely controlled stages of proliferation and 
differentiation, and is dependent upon communication between distinct populations of 
precursor cells. The failure of precursor cells to exit from a proliferative phase and enter the 
differentiation process is a mainstay of embryonal neoplasms [25].  Simplified, embryonal 
tumors can be regarded as a disorder of normal development.  
Neuroblastoma originates from precursor cells of the sympathetic nervous system. During 
neurulation, a developmental step in the embryonic formation of the central nervous system, 
the neural plate, or neuroepithelium, folds in on itself to form the neural tube, a structure that 
will later develop into the brain and the spinal cord (Figure 1). This process of folding brings 
the two outer edges of the plate together to create the transient embryonal structure called 
neural crest. As a consequence, precursor cells from the neural crest then build the dorsal part 
of the neural tube. From this position, a subset of neural crest cells are initiated to undergo an 
epithelial-to-mesenchymal transition (EMT), a process in which cell-cell contacts are 
abrogated, the cytoskeleton is reorganized and cells subsequently acquire a motile phenotype 
[26]. These cells start to migrate along stereotypical migratory pathways, and form a variety 
of diverse cell types, including peripheral neurons, Schwann cells, craniofacial bones, 
melanocytes in the skin, and heart valves, depending on their axial level of origin. Migratory 
neural crest cells from the trunk populate the primordia of the sympathetic ganglia and the 
adrenal gland, and finally differentiate into the sympathoadrenal lineage of sympathetic 
neurons and adrenal chromaffin cells [27, 28].  
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  Figure 1: Border induction and neurulation (from [29], with permission) 
A variety of extracellular signals from the microenvironment (cell-cell and cell-matrix 
interactions) as well as intracellular signaling events induce the complex process of neural 
crest formation, guide the migratory neural crest cells along the migration routes and control 
the sequential process of proliferation and differentiation into the sympathoadrenal lineage 
(reviewed in [29, 30]).  
For example, cells from the non-neural ectoderm or mesoderm secrete Wnt proteins that 
activate Wnt signaling in adjacent cells at the border of the neural plate to initiate neural crest 
formation [31]. In addition, secretion of bone morphogenic protein (BMP), Sonic hedgehog 
(Shh) and fibroblast growth factors (FGFs) are involved in neural crest induction [29, 32]. 
These inductive signals activate genes in neural crest cells known as neural crest specifiers, 
including FoxD3, Snail (Snai1), Slug (Snai2), Sox9 and Sox10 [29]. Neural crest specifiers, in 
turn, are involved in the initiation of the migratory process, e.g. through the repression of 
adhesion molecules like E-cadherin (by Snail [33] and Slug [34]) and the induction of 
Cadherin-7 (by FoxD3 [35]), as well as in the differentiation of post-migratory cells (by Sox9 
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and Sox10 [36]). Differentiation into the sympathoadrenal lineage requires expression of 
BMP family proteins in the neural crest-derived cells [37, 38].  
A strong intracellular stimulus for the ventral migration of neural crest cells is expression of 
the proto-oncogene MYCN. N-myc, the protein encoded by MYCN, is found in moderate 
levels in the nuclei of all trunk neural crest cells before and during migration. After migration, 
cells committed to differentiate into neurons retain high N-myc expression. During neuronal 
maturation, N-myc promotes sympathetic neuronal differentiation in cooperation with other 
intracellular factors (like Mash1 and Phox2b) and extracellular signals (like BMP proteins)[30, 
39, 40]. 
In summary, neural crest cells represent a proliferative cell population that maintains self-
renewal capacity during the migratory course [41]. Disturbances in the spatiotemporally 
precisely controlled processes with consequent inhibition of cell-cycle exit and normal 
differentiation, maintaining proliferation at time points when differentiation is required, can 
initiate the transformation of neural crest cells and, for example, give rise to neuroblastic 
tumors [25]. 
2.1.2 Localization and classification of primary neuroblastic tumors 
The embryonic migration of trunk neural crest cells explains why neuroblastic tumors can 
arise anywhere along the defined migratory routes. The most common sites for neuroblastoma 
are the adrenal medulla (35%), the paravertebral sympathetic ganglia in the abdomen (30-
35%) and mediastinum (20%). Less common sites are the pelvis (3-5%) and the neck (1-5%) 
[42].  
Histologically, the group of neuroblastic tumors consists of several categories that are defined 
according to the maturation degree of the neuroblastic cells and the presence or absence of 
Schwann cell-stromal components in the tumor. The histopathology of neuroblastic tumors 
has been classified in the International Neuroblastoma Pathology Classification (INPC) [43, 
44]. The INPC distinguishes four basic morphologic categories, in which the degree of 
Schwannian stromal development is noted in parenthesis: 
Neuroblastoma (Schwannian stroma-poor) is the most immature variant of neuroblastic 
tumors and consists of small blue round cells with little, if any, features of differentiation 
towards maturing ganglion cells. Neuroblastomas can be further subdivided into 
undifferentiated, poorly differentiated and differentiating tumors. Undifferentiated 
neuroblastomas, in which background neuropil (thin neurite processes) are completely absent, 
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have to be separated by immunohistochemistry from other small blue round cell tumors, like 
Ewing sarcoma/primitive neuroectodermal tumors (PNET), rhabdomyosarcoma, Wilms 
tumors or myeloid sarcoma. The subtype of poorly differentiated neuroblastoma is diagnosed 
when neuropil background is present, but the percentage of cells with ganglion differentiation 
does not exceed 5 %. The subtype of differentiating neuroblastoma is defined as a tumor with 
abundant background neuropil and 5 – 50% of the neuroblasts showing differentiation 
towards ganglion cells.  
On the opposite side of the differentiation scale, the most differentiated category of 
neuroblastic tumors is a ganglioneuroma (Schwannian stroma-dominant). These tumors are 
composed of a dominating Schwann cells stroma with a minor component of ganglion cells of 
different maturation degree. In its completely maturated form, ganglioneuroma lacks any 
neuroblastic component.  
Between the immature neuroblastomas and mature ganglioneuromas, the INPC classifies two 
categories composed of both ganglioneuromatous (“ganglio-“) and neuroblastic components 
(“-neuroblastoma”) and therefore referred to as ganglioneuroblastoma. Neuropil is generally 
abundant. The category of intermixed ganglioneuroblastoma (Schwannian stroma-rich) 
contains well-defined microscopic nests of  “embryonal residues” with neuroblastic cells in 
different maturation stages. The category of nodular ganglioneuroblastoma (composite 
Schwannian stroma-rich/stroma-dominant and stroma-poor) consists of a more heterogeneous 
cell population (“composite”). The neuroblastic cells form nodules in the tumor that are often 
macroscopically apparent and hemorrhagic and contain aggressive malignant cell clones due 
to acquired genetic aberrations or the persistence of malignant clones [43]. 
In a review of 224 neuroblastic tumors [44], the distribution of the INPC categories was as 
following: 190 neuroblastomas (85%), 19 nodular ganglioneuroblastomas (8%), 5 intermixed 
ganglioneuroblastomas (2%), one ganglioneuroma (<1%) and 9 tumors not classifiable (4%). 
2.1.3 Differentiation of neuroblastoma cells 
Although impaired in their physiological differentiation program, most neuroblastoma cells 
retain the capacity to differentiate – spontaneously in vivo, and upon stimulation with various 
agents and growth factors in vitro and in vivo (reviewed in [45]). Spontaneous differentiation 
and regression of neuroblastoma tumors is a peculiar phenomenon in mainly localized tumors 
[15]. These biologically favorable tumors express high levels of the neurotrophic tropomyosin 
kinase receptor A (TrkA), the receptor for nerve growth factor (NGF) [46, 47]. Expression of  
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TrkA appears to mediate either differentiation or apoptosis of neuroblastoma cells, depending 
on the presence or absence of NGF, respectively [48, 49], suggesting that the NGF/TrkA 
pathway is responsible for the differentiation and regression of favorable neuroblastomas [48]. 
Retinoids, like the naturally occurring all-trans-retinoic acid (ATRA) and 9-cis-retinoic acid 
(RA) or the synthetic 13-cis-RA, induce neuronal differentiation and growth arrest of 
neuroblastoma cells both in vitro and in vivo [45]. 13-cis-RA is therapeutically used in 
neuroblastoma treatment ([50], and chapter 2.1.6). Stimulation of the neuroblastoma cell line 
SH-SY-5Y with 12-O-tetradecanoyl phorbol-13-acetate (TPA) induces a strong 
differentiation process, and is used as a model system for mechanistic studies of human 
sympathetic neuronal differentiation. In addition, combinations of growth factors with 
physiologically roles during development of the sympathetic nervous system, like basic FGF 
and insulin-like growth factor 1 (IGF1), induce neuronal differentiation of neuroblastoma 
cells in vitro [45].  Neuroblastoma cell lines generally lack Trk receptors, however, pre-
treatment with retinoids induce Trk expression and sensitize the receptors for their 
neurotrophin ligands (TrkA for NGF; TrkB for brain-derived neurotrophic factor (BDNF) and 
neurotrophin (NTF) -4; TrkC for NTF-3) (reviewed in [45, 49]). Interestingly, the capacity to 
response to exogenous differentiation stimuli is retained even under high MYCN expression 
[51]. Knockdown of MYCN in MYCN-amplified neuroblastoma cells induces neuronal 
differentiation [52]. 
Taken together, the potential of neuroblastoma cells to differentiate, either spontaneously or 
upon distinct triggers, is one of the major neuroblastoma research foci due to fact that 
knowledge about these processes may have direct clinical implication for tumor 
differentiation therapy.  
2.1.4 Molecular aspects in neuroblastoma 
Neuroblastoma is a complex genetic disorder [19, 53, 54]. Acquired somatic aberrations, 
either through segmental chromosomal aberrations like translocations and gene amplification, 
or numerical chromosomal changes, substantially influence tumor biology and clinical 
behavior (see also chapters 2.1.5.3 and 2.1.5.4, and [55]). In addition, several pre-disposing 
germline aberrations have been identified (reviewed in [54]). The following sections will 
review molecular aspects in neuroblastoma, focused on relevance for the papers in this thesis. 
 11 
2.1.4.1 MYCN amplification (MNA) 
Amplification of the human proto-oncogene MYCN is found in approximately 20% of 
neuroblastoma tumors [53]. Due to its profound effect on clinical outcome (see chapter 
2.1.5.3), MYCN-amplification (MNA) is routinely used as a biomarker for treatment 
stratification. The amplification is cytogenetically detectable as autonomously replicating 
double minute chromosomes (dmins), or intrachromosomal homogenously staining regions 
(hsr).  The transcription factor N-myc, which is encoded by MYCN on chromosome 2p24, 
belongs to the Myc-family of DNA binding basic region/helix-loop-helix/leucine zipper 
(bHLHZip) proteins, in which c-Myc, L-Myc and N-myc are the best characterized members 
[56]. The genomic sequences of MYCN and c-MYC share wide structural homology. Both 
genes consist of three exons, where the first exon is untranslated and exon 2 and 3 encode the 
translated regions [57].  N-myc and c-Myc proteins are of similar sizes (464 and 454 amino 
acids, respectively). However, the MYCN mRNA is longer, mainly due to a larger 3'-
untranslated region (3'UTR).  In addition to structural and sequence homologies within the 
Myc-family, the functions of these proteins are closely related. Myc-proteins heterodimerize 
with the bHLHZip-protein Max to a transcription factor complex that binds to specific E-box 
DNA motifs (5'-CANNTG-3') and activates transcription of genes involved in diverse cellular 
functions, including cell growth and proliferation, metabolism, apoptosis and differentiation 
[58-60]. N-myc preferentially binds to the E-box motifs CATGTG and CAACTG. Under 
MNA conditions, however, N-myc becomes less specific and binds additionally to CATTTG 
and CATCTG [61]. In addition to Myc, Max also dimerizes with the bHLHZip-proteins 
Mad/Mnt. These complexes also bind to E-box elements, but repress transcription through the 
recruitment of co-repressors [62]. Through interaction with Sp1 and Miz-1 at promoters, N-
myc has been shown to silence gene expression by recruitment of the histone deacetylase 
HDAC1 [63, 64].  
Dysregulation of Myc activity is an oncogenic hallmark in many human malignancies. Over-
activation of Myc proteins is mainly caused by gene translocations or amplifications, or 
enhanced protein translation or stability, leading to overexpression of a structural normal 
protein [65, 66].  
Given the fundamental role of Myc proteins on cellular processes, their activity in normal 
cells needs to be spatially and timely controlled. While c-Myc is expressed during all 
developmental stages and in a distinct pattern throughout the cell cycle of dividing cells, 
MYCN expression is restricted mainly to the peripheral and central nervous system, kidney, 
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lung and spleen during particular embryonal stages [67]. Expression is controlled at multiple 
levels, including gene transcription through upstream regulators, mRNA turnover, and protein 
activation or decay upon phosphorylation of specific protein residues [56]. In addition, MYCN 
is regulated by microRNAs (see chapter 2.3.10 and paper II).  
The reason why MNA is associated with aggressive tumor biology is still not completely 
understood. Usually, MNA results in overexpression of N-myc protein. Several direct and 
indirect N-myc-targets have been identified, including genes involved in cell cycle regulation 
(e.g. MDM2, MCM7, ODC, and ID2), apoptosis (e.g. TP53), differentiation (e.g. CDC42, 
PAX3), drug resistance (e.g. MRP1) and MYCN stability (Aurora kinase A) (reviewed in [58]). 
In addition, N-myc regulates miRNAs with both oncogenic and tumor suppressor functions 
(see chapter 2.3 and paper I). 
2.1.4.2 Numerical and segmental chromosomal aberrations 
Neuroblastoma tumors harbor numerical chromosomal changes (gains and losses of whole 
chromosomes), segmental aberrations (translocations, amplifications), or combinations of 
both. In a recent study, 224 neuroblastoma tumors were genetically classified according to 
array-CGH profiles to carry either numerical or segmental aberrations alone, in combination, 
or a MNA with or without numerical aberrations (5 groups). Survival dichotomized into 2 
groups: excellent outcome, regardless of stage and age, was found for tumors with solely 
numerical aberrations; segmental aberrations, in contrast, resulted in poor survival. Most 
common segmental alterations were deletions at 1p, 3p and 11q, as well as gains of 1q, 2p and 
17q. Notably, the presence of segmental alterations, whatever their type, was the strongest 
predictor for relapse, regardless of the concomitant MYCN status [55]. The existence of 
tumors with both numerical and segmental changes is indicative for a tumor model in which 
low-grade tumors with numerical changes can secondarily acquire segmental aberrations and 
evolve into aggressive tumors [54]. The fact that the age at diagnosis of mixed profile tumors 
is higher than numerical-only cases, supports the idea of transition, and may be a rationale for 
neuroblastoma mass screening at later ages (see chapter 2.1.7 and [68]).  
2.1.4.3 ALK mutations 
Although chromosomal aberrations are frequent in neuroblastoma, only few mutations in 
typical cancer genes have been reported. In 2008, activating somatic mutations in the 
anaplastic lymphoma kinase (ALK) gene were identified in approximately 6-11% of sporadic 
neuroblastoma tumors [69-73], making ALK to the second major neuroblastoma gene. The 
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oncogenic nature of ALK mutants has been demonstrated in several neuroblastoma in vitro 
systems. Currently, extensive research is ongoing to develop, and clinically evaluate, small 
molecule ALK inhibitors, selectively targeting ALK-mutant neuroblastoma cells (reviewed in 
[74]). 
2.1.4.4 Wnts, the Wnt pathway and DKK3 in neuroblastoma 
The human Wnts are a family of 19 secreted proteins with broad implication in central 
nervous system development [75], including neural crest-derived structures [32, 76], as well 
as many other cellular functions like proliferation, apoptosis, cell adhesion and differentiation 
(reviewed in [77]). Wnt proteins act primarily through the canonical Wnt signaling pathway, 
which finally results in stabilization of the intracellular proto-oncoprotein β-catenin and 
activation of target gene transcription. In detail, but still simplified, Wnt ligands bind to a cell 
surface receptor complex consisting of the proteins frizzled and LRP5 and -6. Binding leads 
to phosphorylation of LRP5/6, which in turn recruits Dishevelled (DVL) proteins to interact 
with frizzled. As a consequence, a destruction complex consisting of APC (adenomatous 
polyposis coli) and axins, which otherwise rapidly degrades β-catenin, is inactivated by 
phosphorylated LRP5/6 and DVL and releases stabilized β-catenin that translocates to the 
nucleus. Here, β-catenin forms a complex with the LEF/TCF transcription factors to activate 
transcriptional targets (reviewed in [78]). 
The identification of proto-oncogenes like c-Myc [79] and N-myc [80] as targets for activated 
Wnt-β-catenin signaling, as well as the detection of mutations in components of the Wnt 
pathway in cancer, broadly connects the Wnt pathway to cancer development (review [81]).  
Mutations in inhibitors of the Wnt signaling pathway are another mechanisms for abnormal 
Wnt signaling contributing to oncogenic transformation. Dickkopf proteins (DKK1-4 and 
soggy) are secreted modulators of the Wnt pathway [82]. DKK1 and -2 antagonize Wnt 
signaling through binding to LRP5/6, which in turn interferes with the receptor´s ability to 
interact with Wnt-bound frizzled. Alternatively, DKKs can interact with the receptor Kremen 
(Krm), leading to endocytosis and destruction of the DKK-Krm-LRP5/6 complex [82].  
The function of DKK3 is more obscure and seems to be dependent on the cell type. DKK3 
acts as an inhibitor of Wnt signaling by blocking β-catenin translocation to the nucleus in 
several cell models, including cancer cell lines [83-85].  In contrast, it has also been shown 
that DKK3 does not interact with LRP5/6, but with Krm. Through internalization of the Krm-
DKK3 complex, the Wnt pathway stays intact and Wnt signaling can be increased [86].  
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DKK3 is a tumor suppressor frequently inactivated by promoter methylation in cancers of the 
cervix [85, 87], liver [88, 89], breast [90], lung [91], mouth [92], and gastrointestinal tract [93, 
94]. In pancreatic carcinoma, high DKK3 expression in tumor vessels was associated with 
favorable outcome and response to cytotoxic treatment [95]. In neuroblastoma, similarly, 
DKK3 expression was higher in prognostic favorable tumors [96]. DKK3 did not seem to 
affect Wnt/β-catenin signaling in neuroblastoma, suggesting other still unknown tumor 
suppressor functions of DKK3 [96]. 
Previous reports have demonstrated that the expression of DKK3 mRNA in neuroblastic 
tumors and neuroblastoma cell lines is inversely correlated to the expression of N-myc [96, 
97]. By modifying MYCN expression with MYCN siRNA or induced MYCN expression, the 
reverse correlation between N-myc and DKK3 mRNA expression was confirmed in several 
neuroblastoma cell lines. However, no direct binding to the DKK3 promoter was identified, 
indicating an indirect regulatory mechanism [96].  
2.1.4.5 Familial neuroblastoma and germline susceptibility genes 
A family history of neuroblastoma can be detected in 1-2% of cases [98]. The majority of 
cases (90%) can be attributed to germ line mutations in either the paired-like homeobox 
PHOX2B gene [99] or the anaplastic lymphoma kinase (ALK) gene [73]. Patients with 
sporadic or familial neuroblastoma in conjunction with other diseases of neural-crest origin, 
like Hirschsprung’s disease and congenital central hypoventilation syndrome, typically have 
PHOX2B mutations. ALK mutations were also found in 5-15% of sporadic neuroblastoma 
cases [71, 73], making ALK to the major neuroblastoma-predisposing gene (see also chapter 
2.1.4.3 and [24]). Genetic testing for ALK or PHOX2B mutations is recommended in patients 
with a family history of neuroblastoma or other disorders of the neural crest to identify 
unaffected siblings with germline mutations who may profit from neuroblastoma screening 
and early diagnosis [53]. 
In addition to mutations in ALK and PHOX2B, several heritable genetic variations (single 
nucleotide polymorphisms, SNPs) in the human genome, identified by genome-wide 
association studies, predispose for the development of sporadic neuroblastomas [24, 53, 100]. 
2.1.5 From histopathology to risk stratification 
The degree of differentiation in neuroblastic tumors, but also other pathological and clinical 
markers like mitosis-karyorrhexis-index (MKI), mitosis rate, stage and age at diagnosis, are 
surrogates for underlying tumor burden and biology [11, 19, 24]. Risk group classification 
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systems incorporating these and other markers attempt to predict the aggressiveness and 
clinical course of an individual tumor. Given the clinical heterogeneity of neuroblastic tumors, 
it is highly relevant for treating physicians to be able to estimate tumor behavior, classify 
patients into risk-groups, and tailor therapy by treatment stratification. In 2009, an 
International Neuroblastoma Risk Group (INRG) Classification System was proposed based 
on a retrospective analysis of 8.800 neuroblastoma patients from North America, Europe and 
Japan [18]. The INRG Classification System (INRGCS) allows assessing risk prior to any 
treatment. The next section will briefly summarize the criteria incorporated in the INRGCS. 
Histological categories and grade of tumor differentiation, both integral parts of the INRGCS, 
have already been discussed in chapter 2.1.2.  
2.1.5.1 Tumor stage 
In 1988 and 1993, an International Neuroblastoma Staging System (INSS) was established 
[101, 102]. The system separated localized (stage 1 and 2) from locoregional (stage 3) and 
metastatic tumors (stage 4). Tumors in infants younger than 1 year with metastases limited to 
the skin, liver or bone marrow, were classified as stage 4S, attributing the fact that these 
tumors have a distinct biology and excellent prognosis with minimal or no treatment due to 
spontaneous regression or maturation (Figure 2). The INSS system is still in use in many 
countries.  
 
Figure 2: The International Neuroblastoma Staging System (INSS) 
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However, a disadvantage of the INSS is that staging is dependent on surgical species, and the 
degree of excision and number of involved lymph nodes may be dependent on the surgeon’s 
expertise and abundance of resected nodes. Therefore, a new staging system (International 
Risk Group Staging System, INRGSS) has recently been proposed [103].  
The INRGSS is based on pre-surgical, radiological characteristics of the primary tumor. 
Through the definition of a set of image-defined risk factors (IDRF), tumors are separated in 
groups with or without IDRFs. Image modalities include CT/MRI and metaiodobenzyl-
guanidine (MIBG) scintigraphy. In addition, bone marrow involvement has to be assessed. By 
these investigations, four disease stages were delineated (Figure 3).  
 
Figure 3: The International Neuroblastoma Risk Group (INRG) staging system 
2.1.5.2 Age at diagnosis 
Age is a strong independent prognostic factor in neuroblastoma. Basically, young children, 
especially under the age of 1 year, have often localized tumors with favorable tumor biology 
and superior prognosis, while the chance for disseminated disease, unfavorable biological 
features and death from refractory disease is continuously increasing in older children [11]. 
Traditionally, the age cutoff for risk classifications in clinical trials has been 12 months.  
However, retrospective data from larger trials revealed that age, as a risk factor, is rather a 
continuum than a binary variable. From statistical and biological standpoints, the optimal 
discriminatory cutoff has been determined to be somewhere between 15 and 19 months [104]. 
The INRG propose 18 months as age cutoff for future risk classifications [18]. 
2.1.5.3 Genetic markers 
The cytogenetic aberration most consistently associated with poor prognosis in neuroblastoma 
is genomic amplification of the proto-oncogene MYCN (see chapter 2.1.4.1). MYCN-
amplification (MNA) in neuroblastoma and its impact on prognosis has been known since 
1984 [105, 106]. MNA correlates strongly with advanced disease and treatment failure [107].  
Hemizygous loss of large segments on chromosome 11q defines another major genetic 
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subtype of high-risk neuroblastoma, and unbalanced deletions of 11q- material are 
independently prognostic for outcome [108]. MNA and loss of 11q are strong inversely 
correlated and can be found in about 70 % of metastatic tumors. Typically, both genetic 
subtypes occur with additional genetic alteration. Loss of chromosome 1p is frequently found 
in MNA tumors, while 11q-loss is significantly associated with gain of 7q and 3p and 4p-loss. 
Gain of 17q-material is frequent in both 11q- and MNA tumors, most often caused by 
unbalanced t(11q;17q) and t(1p;17q) translocations, respectively [54, 109, 110]. Gain of 17q 
is a strong indicator of adverse outcome [111]. 
The MYCN-status and absence/presence of 11q-deletions are risk criteria in the INRGCS [18]. 
The 17q-status was not implemented in the INRG system due to lack of data in the INRG 
study patient cohort [18]. The prognostic value of 1p-deletions is still controversial. Although 
Attiyeh et al. [108] reported 1p-deletions to be independently associated with decreased 
survival in low- and intermediate-risk patients, the INRG data revealed superior overall rates 
at least in low-risk patients regardless of the 1p-status [18]. In the INRGCS, 1p-status is 
therefore not included as a prognostic discriminator. 
2.1.5.4 DNA ploidy 
In general, two main categories of cellular DNA content can be separated in neuroblastoma: 
near-diploid content, or hyperdiploid (often near-triploid) content [112, 113]. DNA content 
(or DNA index) has long been known as a predictor for chemotherapy response for 
neuroblastoma patients < 2 years of age. While hyperdiploidy or near-triploidy was associated 
with long-term survival in these patients, near-diploidy (or tetraploidy) predicted early 
treatment failure [114-116]. Genetic tumor models have suggested that less aggressive 
neuroblastoma cells have mitosis defects, resulting in gains and losses of whole chromosomes 
(numerical chromosomal aberrations) and near-triploid cells. In contrast, aggressive tumors 
are characterized by genomic instability causing unbalanced translocations and chromosomal 
rearrangements (segmental copy number alterations, see also chapter 2.1.4.2) [11, 54, 55, 
112]. The DNA index has been included in the risk assessment of disseminated 
neuroblastoma without MNA in children under 18 months [18].  
2.1.5.5 The International Neuroblastoma Risk Group Classification System (INRGCS) 
In summary, current prognostic factors applied in clinical risk assessment are stage, age at 
diagnosis, histological category and differentiation grade, MYCN- and 11p-status as well as 
tumor DNA ploidy.  
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The pre-treatment risk classification system proposed by the INRG is based on these factors 
and allows the definition of 4 risk groups: very low risk, low risk, intermediate risk and high-
risk (Figure 4). The groups were defined by event-free survival cut-offs (>85% EFS; >75% to 
≤85%; ≥ 50% to ≤75%, or <50%, respectively).  
 
Figure 4: The International Neuroblastoma Risk Group Classification System (INRGCS). Blank field = “any”; 
diploid (DNA index ≤1.0); hyperdiploid (DNA index >1.0, includes near-triploid and near tetraploid tumors); 
GN, ganglioneuroma; GNB, ganglioneuroblastoma; Amp, amplified; NA, not amplified. Modified from [18]. 
The purpose of the INRG classification system is to enable that children diagnosed with 
neuroblastoma in any country of the world can be stratified into homogenous pretreatment 
groups. This will facilitate the comparison of risk-based clinical trials conducted in different 
regions of the world [18]. 
2.1.6 Risk‐adapted treatment and prognosis 
The definition of risk-groups made it possible to conduct cooperative clinical trials with the 
aim to establish, evaluate and optimize risk-adapted treatment of neuroblastoma patients. 
Norway actively participates in the clinical trials designed by the International Society of 
Pediatric Oncology European Neuroblastoma (SIOPEN) research group. Briefly and 
simplified, patients are stratified according to the INRGCS into three treatment protocols: 
Low-risk patients (L1) without MNA are treated according to the LNESG2 protocol by 
surgery alone. L1-patients with MNA, L2- and MS-patients without MNA, and M-patients 
younger than 18 months without MNA were treated according to the LINES protocol. The 
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LINES protocol contains several treatment subgroups in which intensity gradually increases 
from observation alone to combinations of chemotherapy, surgery and irradiation. High-risk 
patients, except those with localized disease, were treated according to the HR-NBL-1 
protocol, one of the most aggressive treatment protocols in pediatric oncology. It combines 
rapid multidrug chemotherapy cycles, tumor surgery, irradiation, high-dose chemotherapy 
with autologous hematopoietic stem cell rescue, and differentiation-inducing treatment with 
13-cis retinoic acid ([50], and chapter 2.1.3). Very recently, immunological targeting of 
residual tumor cells by a combination of subcutaneously injected monoclonal antibodies 
against a neuroblastoma surface antigen (anti-GD2 antibody) and concomitant stimulation of 
the patient’s immune system by interleukin-2 [117] has been implemented into the protocol 
treatment. Immunotherapy against resistant tumor cells either by antibody-based strategies 
[13, 117-120] or haploidentical stem cell transplantation [121] has shown promising results 
for refractory and relapsed disease. 
The 5-year event-free survival (EFS) and overall survival (OS) rates for the complete INRG 
study population of 8.800 neuroblastoma patients was 63% and 70%, respectively [18]. 
Adrenal primary tumor site had significantly worse EFS than other primary sites.  Survival 
rates varied substantially between patients of INSS stages 1,2,3,4S (OS 91% ± 1%) and stage 
4 (OS 42% ± 1%). Disseminated disease with MNA in the tumors showed worst prognosis, 
with OS rates between 22-29%, regardless of age [18]. In contrast, disseminated 
neuroblastomas without MNA in children below the age of 12-18 months have a superior 
prognosis with OS rates exceeding 90 % [18, 122].  
2.1.7 Mass screening  
The dichotomized prognosis of neuroblastoma, with superior survival rates for young patients 
with localized disease contrasted by the poor prognosis for older children with often 
metastasized disease and unfavorable biological features, initiated mass screening studies in 
the 1980-1990s to clarify if long-term survival of high-risk patients can be improved when 
tumors were detected earlier in the course of disease [15, 16, 123, 124]. Mass screening was 
performed by the investigation of urine samples for tumor-secreted catecholamines [123]. In 
fact, screening detected primarily tumors with biological favorable near-triploid DNA content 
that are prone to spontaneous differentiation or can be cured with minimal therapeutic 
interventions [125]. Mass screening at the age of 6 or 12 months increased the incidence of 
neuroblastoma [124], but not long-term survival [16, 17, 126], indicating that aggressive 
tumors either develop de novo at later ages, or have aggressive courses even when detected 
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early. The results from these mass screening studies support the model that neuroblastoma is 
separated into two biological subgroups: favorable tumors in younger children, and tumors 
with unfavorable biology in older children, where the former rarely evolves into aggressive 
types [19]. However, the occurrence of tumors with both numerical and segmental aberrations 
may indicate the possibility for tumor transition (see chapter 2.1.4.2). By now, there is no 
clear indication from prospective studies for population-based mass screening; however, 
screening at the age of 18 months may prove beneficial in prospective studies [68]. 
2.2 MicroRNAs 
MicroRNAs (or miRNAs) are an abundant class of genome-encoded, endogenous, small non-
protein-coding RNA molecules that negatively regulate protein expression in cells [127]. The 
first miRNA, lin-4, was discovered in 1993 in the nematode C.elegans [128, 129]. Since that 
time, miRNAs have been discovered in nearly every organism, from plants and simple 
multicellular organisms to flies, vertebrates and humans. MiRNAs are annotated and 
catalogued in the public-accessible web-based database miRBase (www.mirbase.org)[130-
134], which was founded at the Sanger Institute in England and is now managed by the 
University of Manchester. The current miRBase release 17 (april 2011) annotates 19724 
mature miRNAs in 153 species, including 1719 mature human miRNAs. In humans, the total 
number of annotated mature miRNA sequences has thereby increased by 43% compared to 
the previous release (2010), emphasizing that the complete mapping of all human miRNAs is 
still in progress.  
The biogenesis of miRNAs is a complex multi-step process that starts in the nucleus and ends 
in the cytoplasm of cells (Figure 5; reviewed in [135-138]). Most miRNAs are transcribed as 
long monocistronic or polycistronic primary transcription units (primary miRNA or pri-
miRNA) by RNA polymerase II. Typically, a pri-miRNA is characterized by a hairpin 
structure, containing a double-stranded (ds) RNA stem of ∼33 base pairs (bp), a terminal loop, 
and single-stranded (ss) RNA flanking regions. The stem-loop structure contains the miRNA 
in the 5’ or 3’ half of the stem. The pri-miRNA is cleaved in the nucleus by a protein complex 
(the “microprocessor complex”) consisting of several proteins including the RNase III 
enzyme Drosha and its co-factor DGCR8. DGCR8 functions as a molecular anchor and 
defines the binding site for the microprocessor, while Drosha cleaves the RNA approximately 
11 bp from the ss-dsRNA junction, producing the shorter, ∼ 65-70-nucleotide long hairpin 
pre-miRNA.  
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Following completion of this nuclear processing step, the pre-miRNA is exported from the 
nucleus to the cytoplasm by Exportin-5. Here, the pre-miRNA is cleaved by another RNAse 
III enzyme called Dicer. Dicer cleaves ∼22 nt from the pre-existing end of the pre-miRNA, 
producing ∼22 nt double-stranded RNA molecules. One of the two strands (the guide strand 
or mature miRNA) is, selected upon thermodynamic properties, loaded on an Argonaute 
(Ago) protein, the main constituent of the RNA-Induced Silencing Complex (RISC). The 
other strand (passenger strand) is degraded. The mature miRNA sequence guides the RISC 
complex to recognize and target partial complementary mRNA sequences, primarily within 
the 3’-untranslated region (3’UTR)[136-138]. 
 
Figure 5: Schematic overview over miRNA biogenesis (from [135], with permission) 
Expressional changes of even single miRNAs have profound effects on the protein 
composition in cells [139, 140]. The degree of complementarity between the mature miRNA 
sequence and the target mRNAs determines the mechanism responsible for blocking gene 
expression. Near-perfect pairing, as it is mainly found in plants, causes mRNA destruction 
through Ago-catalyzed mRNA cleavage [141, 142]. In vertebrates, miRNA-mRNA 
interactions are most often through imperfect base pairing [127]. Here, the precise 
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mechanisms behind miRNA-mediated gene silencing is still scientifically debated [143]. 
Destabilization of the mRNA by de-adenylation, de-capping and rapid degradation through 
standard mRNA-turnover processes (“mRNA-destabilization scenario”) seems to be the 
mainstay of miRNA-mediated protein repression [144]. In addition, translational repression 
through blocking translation initiation, or a combination of both mechanisms, is an 
established mechanism to block protein expression [140, 143].  
Different types of miRNA target sites have been identified [145]. In general, target sites are 
characterized by a varying degree of complementarity to the miRNA sequence, and often 
evolutionary conserved between different species (reviewed in [127]).  As shown by studies 
where single nucleotides in miRNA sequences were systematically mutated, sites with as little 
a seven base-pairs of complementarity at the 5’end of the miRNA were sufficient to repress 
the predicted mRNA target in vivo [145]. This complementary sequence at the 5’-position 2-7 
of the miRNA is called “seed”, and is the key determinant for miRNA specificity [146, 147]. 
Four variants of the 6-nt-seed have been identified (Figure 6): the 7mer-m8 site, which 
comprises the seed match supplemented by a match to miRNA nucleotide 8; the 7mer-A1 site, 
which comprises the seed match supplemented by an A across miRNA nucleotide 1; the 8mer 
site, which comprises the seed match supplemented by both the m8 and the A1; and a site 
with only 6 nt perfectly matching (6mer site) [147], resulting in a hierarchy of site efficacy: 
8mer > 7mer-m8 > 7mer-A1 > 6mer [148].  
 
Figure 6: Types of miRNA target sites (adapted from [127, 149]) 
In addition to the seed sequence, complementarity at the 3’-end can both compensate for a 
single mismatch in the seed (3’-compensatory site), as well as increase affinity of the miRNA 
(3’-supplementary sites)[148]. 
The miRNA nomenclature is managed by miRBase and has been slightly changed with up-
coming releases of the database. In general, miRNA names start with a 3-4-letter prefix to 
designate the species (e.g. hsa- for homo sapiens miRNAs). They are further assigned by a 
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three-letter prefix, such as miR- or let-, followed by a sequential number (e.g., miR-1). By 
definition, the mature miRNA is labeled “miR” [132], while the precursor is labeled “mir”; 
however, this discrimination is not stringently used in the literature, and it has been 
recommended to use “mature” or “precursor” when a clear distinction is necessary. Identical 
miRNAs transcribed from different genes are given a numeric suffix, e.g. miR-1–1 and miR-
1–2. Very similar miRNAs (paralogous miRNAs), often sharing the same seed sequence, are 
designated as a “miRNA family” (e.g. mir-29 family) and discriminated by numeric and letter 
suffixes (e.g. mir-29a, mir-29b, mir-29c) [150]. In some cases, two mature miRNAs are 
processed from the same stem-loop precursor, one from each arm, and are accordingly 
designated by an additional suffix “-5p” (for that released from the 5’-arm) and “-3p” (for that 
released from the 3’-arm); e.g., miR-199a-5p and miR-199a-3p. The star-forms (miR*), 
previously used for minor forms, have been “retired” according to the latest nomenclature 
convention [134].  
MiRNA clusters are polycistronic transcription units consisting of several miRNAs located in 
close proximity. In the human genome, more than 85 % of all miRNAs are located within 
intronic regions, while the rest are located within exons [151]. 
As miRNAs tend to target many different mRNAs, and each mRNA may contain several to 
hundreds of different miRNA binding sites, it is obvious that the miRNA-mRNA regulatory 
network is extremely complex. It has been estimated that 30-60 % of all human genes are 
regulated by miRNAs [147, 149]; others suggest that small RNAs, including miRNAs, will 
have the potential to regulate all human genes [137]. A plethora of more than 2.000 review 
articles on miRNA and 20.000 original research papers indexed in PubMed illustrate the 
broad implication of miRNAs in more or less all aspects of cellular function. Established roles 
for miRNAs are their involvement in the development of organisms and organs, in cellular 
processes like proliferation, differentiation, signal transduction and apoptosis, in cell fate 
decisions and immunological defense of viral attacks (reviewed in [138, 152]). As a 
consequence of this broad function, miRNA biogenesis has to be tightly controlled. 
Deregulated miRNA expression has been associated with a diversity of diseases, including 
cancer; a fact attributed in the term “oncomirs” for cancer-related miRNAs. MiRNA 
transcription is regulated by several transcription factors, including oncogenes like c-MYC 




The two very first studies investigating the role of N-myc on miRNA expression in 
neuroblastoma tumors were published by Chen and Stallings in 2007 [156] and Schulte et al. 
in 2008 [157]. Both studies profiled the miRNA expression in a smaller set of primary tumors 
(18 and 24 tumors including 6 and 7 with MNA, respectively) to define differentially 
expressed miRNAs between the MNA and non-amplified groups. Using miRNA-specific 
real-time PCR, Chen and Stallings profiled 157 known miRNAs and reported mainly down-
regulation of miRNA expression in MNA tumors (26 out of 31 differentially expressed 
miRNAs). In contrast, Schulte et al. used a microarray approach, supplemented by real-time 
PCR validation, to profile 384 miRNAs and found exclusively up-regulation of miRNA 
expression (14 miRNAs) in their MNA tumor samples. Among these were several members 
of the oncogenic mir-17-92 cluster as well as four of the five up-regulated miRNAs reported 
by Chen and Stallings.  
The effect of N-myc on miRNA expression was in both studies further investigated by 
altering MYCN expression in neuroblastoma cell lines. Chen and Stallings used anti-MYCN 
siRNA technology to repress MYCN expression in MNA Kelly cells and reported mainly up-
regulation of miRNA expression. The in vitro experimental system used by Schulte et al. is 
based on ectopic over-expression of MYCN cDNA in non-amplified SH-EP cells (SH-EP 
MYCN-ER). Here, they observed up-regulation of 11 miRNAs, 7 of which were also up-
regulated in their MNA tumor samples. Surprisingly, two miRNAs, mir-92 and let-7b, both 
differentially expressed in the experimental cell line models, were correlated to MYCN 
expression in opposite ways in these studies.   
The discrepancies between these two pioneer studies illustrate general methodological 
challenges when studying miRNA expression in neuroblastoma:  
(1) Tumor sample size. The heterogeneous genetic background of neuroblastoma tumors 
requires large tumor sets to delineate miRNA expression signatures for complex genetic 
subgroups. In one of the largest miRNA profiling studies in neuroblastoma so far, Bray et al. 
profiled 430 miRNAs in a total of 145 primary neuroblastoma tumors, including 36 with 
MNA [158]. They found both up- and down-regulated miRNAs (14 and 23, respectively) 
when MNA tumors were compared to non-amplified tumors. Importantly, they also 
determined large-scale genomic gains and losses in each tumor by array-CGH and correlated 
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the genomic localization of differentially expressed miRNAs to chromosomal gains and 
losses. About 15 % of all detectable miRNAs changed expression as a result of chromosomal 
imbalances in the tumors, highlighting that gains or losses of miRNA encoding regions 
contribute significantly to miRNA dysregulation in neuroblastoma, in addition to N-myc 
overexpression.  
(2) MYCN expression.  Experimental systems using MYCN induction or knockdown do not 
reflect two sides of the same coin, but initiate two distinct biological processes, where the 
former results in cell cycle progression and proliferation, while the latter in differentiation and 
apoptosis.  
(3) Profiling platforms. The nature of miRNAs (small size and base-paired structure) poses a 
challenge for miRNA detection techniques [159]. Different technical platforms, like northern 
blotting, high-throughput real-time PCR-techniques, microarray analyses or next-generation 
sequencing, may therefore generate partially diverging expression profiles, mandating 
confirmation between the platforms. 
(4) Number of miRNAs. The number of investigated individual miRNAs varies between 
studies, especially over time, not least because the overall number of identified miRNAs (and 
other small RNA molecules) in the human genome is still increasing. Profiling studies based 
on ultra-deep next-generation sequencing of the total small RNA transcriptome in 
neuroblastoma [160] have the potential to provide ultra-specific and absolute miRNA 
expression data in future studies.  
(5) Functional confirmation. Differential miRNA expression data should be supported by 
functional studies in vitro and in vivo to prove biological relevance of each individual miRNA.  
2.3.2 N‐myc induces miRNA expression – the mir‐17‐92 cluster 
In 2008, Fontana et al. published the first comprehensive functional study on a MYCN-
regulated miRNA cluster – the mir-17-92 cluster [161].  It is transcribed as a polycistronic 
unit from chromosome 13, and comprises 7 individual miRNAs (mir-17, mir-18a, mir-19a, 
mir-19b, mir-20a, mir-92a). Fontana et al. confirmed the observation made by Schulte et al. 
[157], showing that miRNAs of the mir-17-92 cluster are higher expressed in tumors and 
neuroblastoma cell lines with high N-myc expression. By the use of chromatin 
immunoprecipitation (ChIP), they validated direct binding of N-myc to several E-box motifs 
in the mir-17-92 promoter and demonstrated transcriptional activation in luciferase reporter 
gene assays. Moreover, Fontana et al. shed light on the functional consequences of mir-17-92 
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over-expression in MNA neuroblastoma cells: the tumor suppressor p21 (CDKN1A) was 
shown to be targeted by mir-17, and over-expression of mir-17 in non-amplified cells 
increased proliferation, colony-formation and in vivo tumor growth. Vice versa, inhibition of 
mir-17 by antagomirs in MNA cells decreased proliferation and tumorigenesis, and increased 
p21 expression. Surprisingly, antagomir-17 increased apoptosis in neuroblastoma cells; an 
effect not attributable to increased p21. Instead, mir-17 was found to additionally target BIM 
(BCL2 Interacting Mediator of cell death, or BCL2L11), a pro-apoptotic BH3-only member 
of the BCL2 (B-Cell Lymphoma 2) family. In conclusion, Fontana et al. proposed that mir-17 
functions as a major effector of MYCN-mediated tumorigenesis, by targeting p21 while at the 
same time protecting MNA cells from N-myc induced apoptosis through translational 
inhibition of BIM.  
Other studies have confirmed direct binding of N-myc to the mir-17-92 promoter [162, 163], 
as well as a positive correlation between expression of MYCN and members of the mir-17-92 
cluster in primary tumors and/or neuroblastoma cell lines [22, 158, 160, 162, 164-168]. As 
miRNAs simultaneously target a variety of different mRNAs, it became clear that activation 
of the mir-17-92 cluster enables N-myc to turn multiple cellular processes towards malignant 
transformation. In 2009, Beveridge et al. showed that mir-17 and mir-20a target three 
differentiation-associated genes in neuroblastoma cells; BCL2, MEF2D (Myocyte Enhancer 
Factor-2D) and MAP3K12 [169]. Another differentiation-associated protein, the estrogen 
receptor-α (ESR1), was also recently reported to be a target for miRNAs of the mir-17-92 
cluster [162]. ESR1 is expressed in fetal sympathetic ganglia during human neuronal 
development and has been shown to be inversely correlated to MYCN expression in 
neuroblastoma tumors [162]. Loven et al. demonstrated that mir-18a and -19a target ESR1, 
providing a mechanism on how N-myc regulates ESR1 expression [162]. Notably, Loven et 
al. showed that N-myc also binds to E-boxes of the mir-17-92 paralogous miRNA clusters 
mir-106b-25 (chromosome 7) and mir-106a-363 (chromosome X), enabling a concerted 
action of N-myc-activated miRNAs to synergize N-myc functions.  
In a genome-wide proteome analysis, Mestdagh et al. used a tetracycline-inducible mir-17-92 
expression system in non-amplified neuroblastoma cells (SHEP-TR-miR-17-92) to show that 
144 proteins were down-regulated upon mir-17-92 induction, including multiple key effectors 
along the TGF-β signaling cascade [170]. Both TGF-beta receptor type II (TGFBR2) and 
Smad2/Smad4 were shown to be direct targets of mir-17/20 and mir-18a, respectively. 
 27 
Interestingly, TGF-βresponsive genes include p21 and BIM in gastric cancer [171], both 
targets of mir-17-92 in neuroblastoma [161]. 
These studies illustrate how N-myc is able to regulate multiple steps of oncogenic processes 
through the activation of the mir-17-92 cluster (Figure 7).  
 
Figure 7: N-myc induces expression of the mir-17-92 cluster. Several miRNAs in the cluster have been 
confirmed to target genes involved in proliferation, inhibition of apoptosis and inhibition of differentiation. 
2.3.3 N‐myc induces miRNA expression – mir‐9 
Another functionally characterized miRNA positively correlated to MYCN expression is mir-9. 
This miRNA is highly expressed in the brain and other neural tissues and coordinates the 
proliferation and migration of human neural progenitor cells [172]. Recently, Ma et al. used 
an inducible MYCN expression system and genome-wide ChIP-on-chip analyses to confirm 
that mir-9 (at the mir-9-3 locus) is directly activated by N-myc and that mir-9 targets the 
tumor suppressor E-cadherin (CDH1) [165]. E-cadherin is a ubiquitously expressed 
transmembrane glycoprotein on the surface of epithelial cells, with a pivotal role for cell-cell 
adhesion of adjacent cells. E-cadherin function is frequently lost in epithelial cancers and 
associated with invasion and metastasis. In neural crest development, during the process of 
neurulation, down-regulation of E-cadherin allows the neural crest cell to detach from the 
neural tube and migrate along the migratory pathway [27]. Ma et al. found that mir-9 was 
significantly higher expressed in 23 metastasized neuroblastoma tumors (stage 4, all MNA), 
compared to 22 non-amplified tumors without metastases. They demonstrated that mir-9 
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promotes cancer cell motility and invasiveness through the suppression of E-cadherin. 
Moreover, the decrease in E-cadherin increased expression of the pro-angiogenic factor 
VEGFA through activated β-catenin signaling in the cells. The study by Ma et al. propose 
for the first time a model on how N-myc might be able to contribute to metastasis formation 
through the activation of a single microRNA (Figure 8). 
 
Figure 8: Model for N-myc – mir-9 – E-cadherin pathway involved in neuroblastoma metastasis. 
2.3.4 N‐myc induces miRNA expression – mir‐421 
In 2010, a link between disturbed double-strand break (DSB)-induced DNA damage response 
and an N-myc-activated miRNA was reported by Hu et al. [173]. The authors found increased 
expression of mir-421 co-varied with reduced levels of ATM (ataxia-telangiectasia mutated 
kinase) in MNA neuroblastoma cell lines. With the use of a luciferase reporter assay, mir-421 
was shown to directly target the 3’UTR sequence of ATM.  They further demonstrated that N-
myc binds to the promoter region of mir-421 to enhance its expression. This establishes a 
linear signaling pathway (N-myc – mir-421 – ATM) explaining how N-myc negatively 
regulates ATM expression. ATM is a tumor suppressor that transduces the DSB damage 
signals to down-stream effectors of the DNA repair machinery during cell cycle checkpoints 
at G1-S and intra-S phase. Impaired ATM activity leads, most often through gene mutations, 
to genomic instability and predisposes for cancer transformation, especially after radiation 
exposure [174].  In conclusion, this study showed a new mechanism for ATM dysregulation 
related to neuroblastoma tumorigenesis.  
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2.3.5 N‐myc is predominantly a repressor of miRNA expression 
Although several miRNAs have been documented to positively correlate with MYCN 
expression, there is now growing evidence that N-myc predominantly acts repressive on the 
overall miRNA composition in MNA neuroblastoma cells [22, 156, 158, 167, 168, 175] and 
upon N-myc induction in non-amplified neuroblastoma cells [162]. Lin et al. profiled the 
expression of 162 miRNAs in 66 primary neuroblastoma tumors (including 13 with MYCN-
amplification) and found a nearly global down-regulation of miRNAs in high-risk tumors, 
especially in those with MYCN-amplification [175]. The authors hypothesized that 
dysregulation in Dicer and/or Drosha, key enzymes in the miRNA processing pathway, may 
contribute to the widespread miRNA down-regulation. Indeed, both Dicer and Drosha were 
lower expressed in stage 4 tumors compared to other stages, with the most strikingly 
differential expression between stage 4 and stage 4S. This suggests that repression of 
miRNAs may be involved in tumor progression.  
2.3.6 N‐myc‐regulated tumor suppressor miRNAs in neuroblastoma 
Chen and Stallings found that mir-184 was significantly down-regulated in MNA tumors and 
up-regulated upon MYCN-knockdown in a MNA neuroblastoma cell line [156]. 
Overexpression of mir-184 reduced cell viability of both MNA and non-amplified cell lines 
through the induction of apoptosis and G1 cell cycle arrest. A follow-up study by Foley et al. 
confirmed the inverse correlation between N-myc and mir-184 in primary tumors and showed 
that inhibition of mir-184 by antagomir treatment increased proliferation of neuroblastoma 
cells [176]. Moreover, they demonstrated that mir-184 directly targets AKT2 (Protein kinase 
B beta). AKT2 is a down-stream effector of the phosphatidylinositol 3-kinase (PI3K) pathway, 
one of the most potent pro-survival pathways in cancer. Activation of AKT is associated with 
poor prognosis in neuroblastoma [177]. Finally, Tivnan et al. used an in vivo murine 
xenograft model where mir-184-transfected MNA or non-MNA neuroblastoma cells were 
orthotopically injected into CB-17/SCID mice [178]. Tumors arising from mir-184-
transfected cells were smaller than the controls, and mice survived longer. In summary, these 
comprehensive studies clearly established MYCN–regulated mir-184 as a tumor suppressor in 
neuroblastoma.  
Another tumor suppressor miRNA repressed by N-myc is mir-542-5p.  Several studies have 
shown an inverse correlation between mir-542-5p and MYCN-amplification in primary tumors 
[22, 158, 160, 179]. In a large-scale profiling study of 430 miRNAs in 69 primary tumors, 
Schulte et al. found increased expression of 4 miRNAs in MNA tumors while 35 miRNAs 
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were repressed, including mir-542-5p [22].  Mir-542-5p expression was found to be 
predictive for outcome, with a significantly higher expression in patients with event-free 
survival compared to relapsed patients. Bray et al. profiled the expression of 449 miRNAs in 
145 neuroblastoma tumors and correlated mir-542-5p expression to clinical data [179]. 
Expression of mir-542-5p was non-randomly distributed among tumor genetic subtypes, with 
lowest expression in MNA tumors (77 % completely lacking expression) and highest 
expression in stage 1,2,3 and 4S tumors. Patients with tumors lacking mir-542-5p expression 
had the poorest prognosis, independently of the MYCN status in the tumors [22, 179]. Bray et 
al. further demonstrated that mir-542-5p overexpression in MNA and non-MNA 
neuroblastoma cells reduced invasiveness in vitro, and restricted tumor growth and metastasis 
in vivo when cells were orthotopically injected into mice.  
2.3.7 Genome‐wide analysis of N‐myc‐regulated miRNAs 
So far, only two studies have used a next-generation sequencing approach to analyze 
activation or repression of miRNAs by N-myc on a genome-wide basis [160, 168]. Schulte et 
al. used ultra-deep SOLiD sequencing to compare the total small RNA transcriptome in 5 
unfavorable MNA tumors with 5 favorable non-MNA tumors [160]. Analyzing the absolute 
number of miRNA reads, there was a trend toward a higher proportion of mature miRNAs in 
the favorable patient group, indicating a possible global suppression of miRNA transcription 
in MNA tumors. Expression data of 204 miRNAs were validated by RT-qPCR with good 
correlation between the technical platforms. The SOLiD sequencing data confirmed 
previously data on differential expression in MNA versus non-MNA tumors, including the 
mir-17-92 cluster and mir-181 (positive N-myc-correlation) and mir-542-5p (nearly absent in 
MNA tumors). In total, 76 miRNAs were differentially expressed between MNA and non-
MNA tumors (43 up-regulated and 33 down-regulated). Next-generation sequencing allowed 
the discovery of several new miRNAs in neuroblastoma and revealed insight into miRNA 
editing and distribution of mir-5p/-3p and mir* forms. In addition, cluster analysis was able to 
exactly separate the two clinical outcome groups based on their differential miRNA 
expression, indicating that the miRNA transcriptome reflects tumor aggressiveness [160].  
Very recently, Shohet et al. performed a genome-wide study of N-myc binding sites in 
promoters driving miRNA expression in neuroblastoma [168]. Using a combination of ChIP 
and Massively Parallel Sequencing (ChIP-seq) in a neuroblastoma cell line with inducible N-
myc expression, they identified 20 gene promoters, hosting a total of 30 miRNAs, to which 
N-myc specifically bound to E-box motifs.  The majority of host genes that were correlated 
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with survival were down-regulated by high N-myc levels, suggesting a tumor suppressor 
function for these host genes as well as the co-expressed intronic miRNAs. However, 
functional studies of two MYCN-regulated intronic miRNAs (mir-591 and mir-558) identified 
tumor suppressor functions for mir-591 as expected, while mir-558 was reported to function 
as an oncomir. These data are supportive for the hypothesis that N-myc has to restrain growth 
as well as to promote it during the processes of tumor initiation and tumor transformation 
from neural crest cells to undifferentiated malignant tumor cells [168]. 
2.3.8 C‐myc/N‐myc‐induced miRNAs repress gene networks 
In a large-scale miRNA expression study, Mestdagh et al. profiled the expression of 430 
miRNAs in 95 neuroblastoma tumors and delineated a signature of 50 unique miRNAs 
differentially expressed between MNA and MYCN single-copy tumors (16 up-regulated and 
34 down-regulated miRNAs) [167]. Interestingly, the miRNA signature further delineated 2 
distinct tumor sub-groups within the MYCN single-copy group: tumors with high or low c-
myc expression. The three tumor groups defined by the 50-miRNA signature correlated well 
with the clinical stage and prognosis. Mestdagh et al. concluded that MYCN/c-MYC 
signaling rather than MYCN-amplification alone underlies the differential expression of 
miRNAs in neuroblastoma. To identify mRNA targets down-stream of the MYCN/c-MYC-
regulated miRNAs, they integrated mRNA and miRNA expression data sets from 40 
neuroblastoma tumors and calculated correlations between each of the 50 miRNAs and 
around 15 000 mRNAs. In the group of mRNAs with inverse miRNA correlation, significant 
3’UTR seed enrichment was only found for the 16 N-myc-activated miRNAs, indicating that 
these miRNAs have a widespread effect on differential gene expression in high-risk 
neuroblastoma. One third of the mRNAs were predicted targets of two or more MYCN/c-
MYC-activated miRNAs, indicating a concerted action towards target gene suppression. Low 
expression of predicted mRNA targets in the tumors correlated with a particular poor patient 
prognosis. MYCN/c-MYC-activated miRNAs were predicted to repress several pathways 
known to be involved in neuroblastoma, including integrin signaling.  In summary, the study 
by Mestdagh et al. comprehensively demonstrated widespread transcriptional repression of 
coding genes by MYCN/c-MYC through miRNA induction, serving as an additional 
mechanism of MYCN/c-MYC induced oncogenicity. 
2.3.9 MiRNA expression and neuroblastoma differentiation 
Several studies have used retinoic acid (RA)-treatment of MNA neuroblastoma cells as a 
model system to investigate the role of miRNAs during MYCN knockdown followed by 
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neuronal differentiation [156, 180-184]. During RA exposure of MNA neuroblastoma cells, 
N-myc is immediately down-regulated prior to the onset of morphological differentiation 
([185], and chapter 2.1.3). Several individual miRNAs whose expression is changed during 
RA-induced differentiation have been functionally characterized.  Mir-152 was found to 
target DNMT1 (DNA methyltransferase 1)[180]. Diminished DNMT1 leads to decreased 
promoter methylation, allowing transcriptional activation of target genes like NOS1 (nitric 
oxide synthetase), a pro-differentiation signaling molecule. Strikingly, mir-152 was found to 
be repressed by N-myc in an N-myc-repressible in vitro cell system, consistent with the 
model of RA-induced N-myc repression and consecutively up-regulation of mir-152 during 
the differentiation process. Mir-10a/b was up-regulated during RA-treatment of both MNA 
[181] and non-MNA [186] neuroblastoma cells. Mir-10a/b was shown to target NCOR2 
(nuclear receptor corepressor 2), and both exogenous overexpression of mir-10a/b as well as 
siRNA-mediated knockdown of NCOR2 in MNA neuroblastoma cells resulted in 
phenotypical changes compatible to RA-treatment, including indirect reduction of N-myc 
levels [181].  Mir-9 and mir-125, up-regulated upon RA-treatment, target t-TrkC, a truncated 
form of TrkC (tropomyosin-related kinase C). Truncated-TrkC in turn abrogates the function 
of full-length TrkC whose expression in primary tumors is correlated with good prognosis.  
Thus, in the context of differentiation, mir-9 seems to have onco-suppressive and pro-
differentiation properties. On the other hand, as highlighted before, mir-9 is directly activated 
by N-myc with pronounced oncogenic properties in proliferating neuroblastoma cells [165].  
Laneve et al. demonstrated that during RA-differentiation and consecutively decreasing N-
myc activity, the mir-9 promoter is activated through phosphorylation of CREB and dismissal 
of repressing REST [187]. These studies illustrate that the same miRNA may exhibit 
opposing effects during distinct cellular processes, as a consequence of diverse promoter 
activation and executed by a different set of miRNA targets. 
2.3.10 MYCN is targeted by miRNAs 
Finally, MYCN itself is targeted by miRNAs. The functionally best characterized MYCN-
targeting miRNA is mir-34a [188, 189], which is located at chromosome 1p36, a region 
frequently deleted in MNA neuroblastoma tumors [11]. MiRNA-regulation of MYCN has 




As outlined, MYCN-amplification (MNA) has a strong impact on survival in neuroblastoma. 
However, it is still not completely understood how N-myc contributes to the aggressive 
phenotype. MiRNAs are regulators of gene expression and, when deregulated, involved in 
cancer development. Therefore, the thesis addressed the following general questions:  
 
1. How does the proto-oncogene MYCN influence the expression of miRNAs in 
neuroblastoma?  
For this purpose, we used an approach where we transiently down-regulated N-myc 
expression in MNA neuroblastoma cells by anti-MYCN shRNA, and analyzed 
subsequent changes in miRNA expression by miRNA microarray studies. The results 
are published in paper I.  
The establishment of anti-MYCN shRNA is described in a method paper (appendix). 
 
2. Are miRNAs, in turn, regulators of MYCN expression in neuroblastoma?  
For this purpose, the MYCN 3’UTR was systematically screened for miRNA binding 
sites. Validated MYCN-regulating miRNAs were functionally characterized. The 
results are published in paper II.  
 
3. What are targets and cellular functions of N-myc-regulated miRNAs?  
We focused on mir-92, which is regulated by N-myc (paper I) and belongs to the 
oncogenic mir-17-92 cluster, and experimentally investigated its predicted role to 




The following methods are regarded as standard methods in molecular and cellular biology, 
and therefore not discussed in detail in this thesis, but thoroughly described in each paper: 
Cell culture techniques; cloning of expression plasmids; sequencing; transfection of cells with 
Lipofectamin; retroviral transduction of cells; qualitative and quantitative real-time RT-PCR; 
Western blotting; ELISA test; Alamar blue cell proliferation assay; clonogenic assay; 
flowcytometric cell cycle analysis. 
4.2 Cell lines 
The following cell lines were used in paper I, II and III: MNA neuroblastoma cell lines: 
Kelly (N206); SK-N-BE(2); SMS-KCN; SMS-KCNR; SMS-KANR; IMR-32, LAN-5. Non-
MNA NB cell lines: SK-N-AS; SH-SY-5Y; SK-N-SH. 
SH-EP-Tet21N cells are non-MNA neuroblastoma cells stably expressing high MYCN levels 
under the control of a tetracyclin repressor, meaning that the addition of tetracyclin, or its 
more stable homologue doxycycline, to the culture media switches-off MYCN expression 
[190]. 
In paper II and III, the human embryonic kidney cell lines HEK293 was used in luciferase 
reporter assays. 
4.3 Patient tumor samples  
For paper II and III, we received genomic DNA from neuroblastoma tissue samples obtained 
during surgery (biopsy) from neuroblastoma patients treated at the University Hospitals in 
Gothenburg and Stockholm, Sweden. Patient samples did not include patients’ identification, 
but information about the MYCN status in the sample. Use of the material was approved by 
the ethical committees of the institutions (Karoliniska Institute, Gothenborg University).  
4.4 Design of anti‐MYCN shRNA molecules 
The design, cloning, validation and cellular effect of anti-MYCN shRNA is described in detail 
in the appendix paper Henriksen JR, Buechner J, Lokke C, Flaegstad T, Einvik C: Inhibition 
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of gene function in mammalian cells using short-hairpin RNA (shRNA). Methods Mol 
Biol 2011, 703:189-204. In paper I, we used the anti-MYCN shRNA aMN-887. In paper III, 
the retrovirally transduced shRNA aMN-1658 was used [52]. 
4.5 Computational miRNA target prediction 
MiRNAs are only partially complementary to respective target mRNAs. The identification of 
miRNA target sequences in the genome is therefore challenging. For this purpose, several 
bioinformatics algorithms have been developed and build the basis for public available 
miRNA target prediction software programs (reviewed in [191]). Common for all algorithms 
is the inclusion of several known miRNA target site features to recognize miRNA target sites 
in the genome. These features include: seed site characteristics (e.g. 6-8mers, pairing in the 
3’part of the miRNA, see chapter 2.2); site location (e.g. within a 3’UTR structure); 
conservation of the miRNA and the corresponding target site across species; site accessibility 
(e.g. secondary structure of the 3’UTR); the existence of several target sites within the same 
UTR; and plausible correlation between miRNA- and mRNA expression profiles (all 
reviewed in [191]). None of the currently available prediction programs incorporate all these 
features in their algorithms. Therefore, to increase specificity of the prediction, it is 
reasonable to intersect results from one prediction with results from other prediction programs.  
In paper II, we combined three miRNA target prediction programs, TargetScan 5.1 [146] 
(www.targetscan.org), MiRanda [192] (www.microrna.org) and PicTar [193] 
(http://pictar.mdc-berlin.de) to identify MYCN-targeting miRNAs. Predictions from 
TargetScan, which uses site and miRNA conservation across different species as selection 
criteria, were intersected with the predictions from the MiRanda and PicTar programs. In 
paper III, TargetScan was combined with MicroCosm [132] (formerly mirBase target, 
http://www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5) and Diana MicroT v.3.0 [194] 
(http://diana.cslab.ece.ntua.gr/microT/). 
4.6 MiRNA microarrays 
In paper I, we performed 2 independent miRNA expression studies on SK-N-BE(2) cells 
transfected either with a plasmid containing the anti-MYCN shRNA aMN-887, or a control 
shRNA. As these transfections were of transient nature, cells were harvested three days after 
transfection; a time-point when MYCN expression is knocked down and neuronal 
differentiation becomes morphologically apparent (appendix paper). Total RNA was 
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isolated with the miRVana miRNA isolation kit (Ambion) according to the manufacturer’s 
instructions. The miRNA microarray assay started with 10 ng total RNA.  
We used a commercial miRNA microarray service provider (lcsciences.com) to perform the 
microarray analyses, as this method is not yet established at the University of Tromsø. The 
technical details of the assay, including miRNA enrichment, fluorescent dye labeling and 
hybridization conditions, are described elsewhere [195]. LCSciences uses γParaflo 
Microfluidic Biochips.  Compared to spotted microarrays, microfluidic chips have the 
advantage that the miRNA detection probes are synthesized by photochemistry directly in the 
microchambers that will be flooded with the custom RNA sample (see www.lcscience.com). 
This miRNA synthesis step immediately prior to each array experiment always guarantees the 
latest Sanger miRNA set to be investigated, and allows adding of custom small RNA probes.  
The data analysis of the microarrays was part of the provider service, as this is a complex and 
highly expertise-demanding process, which includes subtraction of the background and a 
normalization step. After normalization, the p-values of the difference between the two 
fluorescent signals were calculated. Differentially expressed miRNAs were those with a p-
value <0.01 in at least 50% of the array replicates (more details in paper I).  
Microarray results were confirmed by miRNA-specific RT-PCR on the same RNA 
preparation as used on the microarray, as part of the provider service.  
4.7 miRNA‐specific real‐time RT‐PCR 
The expression of miRNAs and small RNA control molecules (SNORD38B) in paper I and 
III were measured using the Qiagen miScript SYBRGreen PCR Kit and specific primer sets 
(Qiagen). Results were analyzed using the ΔΔCT method with qBase software [196]. 
4.8 Luciferase reporter assay (LRA) 
This assay was used in paper II and III to investigate if a miRNA binds to the MYCN and 
DKK3 3’UTR structures, respectively. For this purpose, the full-length 3’UTR structures were 
cloned into a firefly luciferase expressing plasmid (pMIR-REPORT) down-stream of the 
luciferase gene. Binding of miRNAs to the 3’UTRs will cause down-regulation of the 
luciferase activity. MiRNAs, the pMIR-3’UTR plasmids, and a plasmid expressing a Renilla 
luciferase (for luciferase normalization) were transfected into HEK293 cells. 48 hours after 
transfection, Renilla and Firefly luciferase activities were analyzed using the Dual Luciferase 
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Assay (Promega). Each miRNA transfection was done in triplets and independently repeated 
at least three times, resulting in at least nine (but up to > 30) LRAs for each individual 
miRNA. Luciferase activities were analyzed in duplicates. Normalization included two steps: 
first, the Firefly luciferase activity was normalized to the Renilla luciferase activity, and 
second, the normalized luciferase activity of transfected NC (pre-mir-346 or Negative Control 
mimic) was set as relative luciferase activity of 1. The PASW Statistics 18 software was used 
for data analyses and boxplot charts. 
4.9 Site‐directed mutagenesis 
Site-directed mutagenesis was used to specifically mutate individual miRNA seed sequence 
of selected miRNAs (paper II and III, as described in detail). Two-base mismatch mutations, 
introduced within position 2-6 of the seed, have been shown to disrupt miRNA-binding 
capacity [197]. LRAs with either wild-type or mutated seed sequences were performed and 
compared. In case of a specific miRNA-mRNA interaction, destruction of the seed will cause 
a rescue in luciferase activity and validate the binding of the miRNA. In non-rescued cases, 
we extended the mutagenesis to include a complete seed mismatch (complete position 2-7).  
4.10 Immunofluorescence confocal laser microscopy  
Morphological changes and in situ N-myc expression were evaluated by immunostaining and 
confocal laser microscopy. Confocal laser microscopy, as compared to wide-filed standard 
immunofluorescence microscopy, has the advantage to serially produce thin optical sections 
through a fluorescent-stained specimen through incremental changes in the microscope fine 
focus mechanism. The serially acquired images can be computationally merged to generate a 
stacked image with a nearly three-dimensional perspective. The specimen can be stained with 
multiple combinations of different primary antibodies and secondary fluorescent antibodies, 
which can be distinguished on the same specimen by the use of filters in the microscope 
excluding unwanted fluorescence wavelengths. As SK-N-BE(2) neuroblastoma cells develop 
long neurite outgrowths during neuronal differentiation (paper I), we had to establish a 
protocol which prevents the detachment of cells and neurites during the repeated steps of 
staining and washing, in addition to prior transfection. We cultured cells on round poly-L-
lysine coated glass slides, transfected them in six well dishes, and fixated three days after 
transfection with 4% paraformaldehyde. After permeabilization with ice-cold MeOH 
and blocking with BSA, cells were incubated with primary antibodies, and covalent bindings 
visualized by fluorescent secondary antibodies. Cell nuclei were stained with Draq5. We used 
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a Zeiss LSM500 confocal microscope, the software LSM Image Browser (Zeiss) and an 
Adobe Illustrator for image processing and preparation. 
4.11 xCELLigence cell proliferation system 
The xCELLigence System (Roche, Mannheim, Germany) monitors proliferation of cells 
continuously in real-time, without the need to incorporate any labels. The system is based on 
the measurement of electrical impedance across interdigitated micro-electrodes integrated on 
the bottom of special tissue culture plates (E-Plates, Roche). The impedance measurement 
provides quantitative information about the biological status of the cells. During proliferation, 
i.e. growth and division of cells, micro-electrodes are increasingly inter-connected, leading to 
changes of electrical impedance. These impedance changes can be calculated as a “cell index” 
that correlates to cell proliferation. An advantage of this method is the continuous, real-time 
documentation of cellular proliferation, which can be displayed as growth curves and make 
comparison of proliferation, or other growth parameters like doubling time, easily visible. As 
a prerequisite for this assay, cell density has to be optimized to insure that the cells do not 
reach confluence during the observation period. 
In paper II, we seeded Kelly cells in 160 µl media (15 000 cells per well) in 16-well E-plates 
and transfected them in triplicates 4–6 h later with 60 µl of a transfection mix containing 0.2 
µl Lipofectamine2000 and 0.6 µl miRNA mimic (20 µM). Proliferation was recorded 





Buechner J, Henriksen JR, Haug BH, Tomte E, Flaegstad T, Einvik C: Inhibition of mir-21, 
which is up-regulated during MYCN knockdown-mediated differentiation, does not 
prevent differentiation of neuroblastoma cells. Differentiation 2011, 81:25-34. 
 
In this study, we investigated the role of N-myc on miRNA expression in MYCN-amplified 
neuroblastoma cells. We performed a miRNA profiling study on SK-N-BE (2) cells, and 
determined differentially expressed miRNAs upon MYCN knockdown using anti-MYCN 
short-hairpin RNA (shRNA) technology. 
MYCN knockdown induced strong neuronal differentiation of the SK-N-BE(2) cells, as 
demonstrated by morphology and the expression of neuronal markers. Two independent 
miRNA microarray analyses revealed 23 miRNAs consistently differentially expressed during 
MYCN knockdown-mediated neuronal differentiation. The expression changes were 
bidirectional, with 11 and 12 miRNAs being up- and down-regulated, respectively. Among 
the down-regulated miRNAs, we found several members of the oncogenic mir-17-92 family, 
including mir-92a. Mir-21, an established oncomir in a variety of other cancer types, was 
strongly up-regulated upon MYCN knockdown and subsequent differentiation. This 
observation was therefore further investigated by functional analyses of mir-21 in the MYCN-
amplified cell lines SK-N-BE(2) and Kelly. Neither overexpression of mir-21 in the high-
MYCN neuroblastoma cells, nor repression of increased mir-21 levels during MYCN 
knockdown-mediated differentiation had any significant effects on cell differentiation or 
proliferation.  
In conclusions, we describe a subset of miRNAs that were altered during the MYCN 
knockdown-mediated differentiation of MNA-amplified neuroblastoma cells. In this context, 
N-myc acts as both an activator and suppressor of miRNA expression. Mir-21 was up-
regulated during cell differentiation, but inhibition of mir-21 did not prevent this process. We 
were unable to establish a role for mir-21 during differentiation and proliferation of the two 
neuroblastoma cell lines used in this study. 
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5.2 Paper II: Brief summary 
Buechner J, Tømte E, Haug BH, Henriksen JR, Løkke C, Flægstad T, Einvik C: Tumour-
suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit 
cell proliferation in MYCN-amplified neuroblastoma. Br J Cancer 2011, 105:296-303. 
 
MicroRNAs (miRNAs) regulate expression of many cancer-related genes through 
posttranscriptional repression of their mRNAs. In this study, we investigate the proto-
oncogene MYCN as a target for miRNAs.  
By genomic sequencing of the 3’-untranslated region (3’UTR) of MYCN in 7 MYCN-
amplified neuroblastoma cell lines as well as 39 primary tumors (both MYCN-amplified and 
MYCN single-copy), we found only one single nucleotide polymorphism (SNP) in the 3’UTR 
of MYCN, demonstrating that mutations in the miRNA binding sequence are rare.  
A luciferase reporter assay was used to investigate software-predicted miRNA target sites in 
the MYCN 3’UTR. The miRNAs were overexpressed in the HEK293 cell line by transfection 
of miRNA mimics or miRNA-expressing plasmids. Mutation of the potential target sites by 
site-directed mutagenesis was used to validate the MYCN 3’UTR as a direct target of several 
miRNAs.  
To measure miRNA-mediated suppression of endogenous N-myc protein, as well as effects of 
MYCN-targeting miRNAs on proliferation and clonogenic growth, miRNAs were 
overexpressed in the MNA neuroblastoma cell line Kelly.  
The study showed that MYCN is targeted by several miRNAs. In addition to the previously 
documented mir-34a/c, we experimentally validated mir-449, mir-19a/b, mir-29a/b/c, mir-
101 and let-7e/mir-202 as direct MYCN-targeting miRNAs. These miRNAs were able to 
suppress endogenous N-myc protein in MYCN-amplified neuroblastoma cells. Especially let-
7e and mir-202 were strong negative regulators of MYCN expression. The mir-101 and the 
let-7 family miRNAs let-7e and mir-202 inhibited proliferation and clonogenic growth when 





Haug BH, Henriksen JR, Buechner J, Geerts D, Tomte E, Kogner P, Martinsson T, Flaegstad 
T, Sveinbjornsson B, Einvik C: MYCN-regulated miRNA-92 Inhibits Secretion of the 
Tumor Suppressor DICKKOPF-3 (DKK3) in Neuroblastoma. Carcinogenesis 2011, 
32:1005-1012. 
 
Dickkopf-3 (DKK3) is a secreted protein of the Dickkopf family of Wnt regulators. It 
functions as a tumor suppressor in a range of cancers, including neuroblastoma. MYCN was 
recently found to down-regulate DKK3 mRNA. In this study, we investigated if the DKK3 
repression is mediated by MYCN-regulated miRNAs.  
First, we demonstrated that MYCN knockdown in MNA neuroblastoma cell lines increases 
secretion of endogenous DKK3 protein to the culture media.  
We then used miRNA target prediction software to identify MYCN-regulated miRNAs that 
could potentially target the 3’UTR sequence of DKK3. Luciferase reporter assays and seed 
mutagenesis were used to validate miRNA-DKK3-3’UTR interactions.  
Several MYCN-regulated miRNAs were predicted to target DKK3, including mir-92a and 
mir-92b (paper I), and let-7e. Luciferase expression from a reporter vector containing the 
DKK3-3`UTR was decreased when this construct was co-transfected with mir-92a, mir-92b 
or let-7e in HEK293 cells. Site-directed mutation of the mir-92 seed sequence in the 3’UTR 
completely rescued the observed decrease in reporter expression when co-transfected with 
mir-92a and mir-92b.  
Antagomir and miRNA-mimic transfections in neuroblastoma cell lines confirmed that DKK3 
secretion to the culture media is regulated by mir-92s.  
Consistent with reports from other cancers, we found DKK3 to be expressed in the 
endothelium of primary neuroblastoma samples and to be absent in tumors with MNA. 
In conclusion, the study demonstrated that MYCN-regulated miRNAs are able to modulate the 





MYCN is amplified in a subgroup of neuroblastomas with highly aggressive behavior [18]. 
Our group has previously established an efficient model system to selectively down-regulate 
MYCN expression in MNA neuroblastoma by specific anti-MYCN shRNA molecules 
(appendix paper). This approach allows us to investigate and compare cellular processes in 
both high- and low-MYCN neuroblastoma cells. In particular, this model system can be used 
to study neuronal differentiation in MNA neuroblastoma initiated by specific MYCN 
knockdown, as opposed to induced neuronal differentiation using protocols with RA, TPA or 
various combinations of growth factors (e.g. BDNF, NGF, IGF1, FGF) (see chapter 2.1.3 and 
review [45]). In paper I, we used plasmid-encoded anti-MYCN shRNA to induce transient 
MYCN-knockdown (as described in the appendix paper). In paper III, anti-MYCN shRNA 
was expressed in neuroblastoma cells using a tetracycline-inducible retroviral delivery system. 
This expression system allows us to conditionally repress MYCN expression in MNA 
neuroblastoma cells (as described in [52]).  
6.2 MYCN knockdown alters miRNA expression in MNA cells  
As thoroughly introduced in chapter 2.3, several studies have addressed the role of N-myc on 
the expression of miRNAs in neuroblastoma over the past few years. These studies were 
mainly performed by overexpressing MYCN in non-MNA neuroblastoma cell lines with or 
without the capacity to undergo neuronal differentiation [156-158, 161, 162, 165, 167, 173, 
176, 180], or by comparing miRNA profiles in MNA versus non-MNA neuroblastoma tumors 
[22, 156-158, 160, 161, 164, 165, 167, 170, 175, 176, 198-201]. 
As outlined in chapter 2.3.9, the contribution of miRNAs to the neuronal differentiation 
processes in neuroblastoma has mainly been investigated in SH-SY-5Y cells induced to 
differentiate by the addition of TPA or RA alone, or RA in combination with BDNF [156, 
169, 180-184, 186, 200, 202, 203].  
In paper I, we analyzed the expression of 723 known human miRNAs during the 
differentiation of MNA SK-N-BE (2) cells upon MYCN knockdown. By comparing miRNA 
expression levels in high and low N-myc SK-N-BE (2) cells, we found 23 differentially 
expressed miRNAs. Twelve miRNAs (mir-17, -18a, -20, -24, -25, -92a, -92b, -93, -103, -
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106a, -494 and mir-495) were down-regulated, and 11 miRNAs (mir-21, -22, -126, -137, -
181d, -218, -663, -671, let-7c, let-7d and let-7f) were up-regulated. 
Knockdown of MYCN expression in MNA neuroblastoma cell lines by small RNA molecules 
(siRNA or shRNA) initiates a distinct neuron-like differentiation process characterized by 
morphological (neurite outgrowth) and biochemical (up-regulation of neuronal markers) 
changes [52]. Two studies using anti-MYCN siRNA or shRNA to investigate miRNA 
expression during MYCN knockdown-induced differentiation of MNA neuroblastoma cells 
have been published ([156] and paper I). These studies report complementary rather than 
identical results most likely due to different knockdown techniques and cellular systems. 
While Chen and Stallings used the siRNA approach to confirm a correlation between N-myc 
and miRNAs differentially expressed in MNA versus non-MNA primary tumors, we used 
shRNA to investigate an unbiased pool of 736 miRNAs (paper I). In accordance with our 
data, Chen and Stallings found mir-137, mir-181 and let-7 family members among the up-
regulated miRNAs. 
Both up- and down-regulation of miRNAs was observed upon MYCN knockdown (paper I). 
Among the down-regulated miRNAs, most were members of the oncogenic miRNA clusters 
that constitute the mir-17-92 family. It is well established that N-myc is a transcriptional 
activator by direct binding to the promoter regions of several miRNAs, including the mir-17-
92 family clusters (chapter 2.3.1 - 2.3.4). In addition, miRNAs of the mir-17-92 family 
clusters have been shown to be down-regulated in non-MNA neuroblastoma cells in which 
differentiation was induced by various agents and growth factors [169]. In paper I, we 
showed for the first time that most miRNAs belonging to the mir-17-92 family are down-
regulated upon the MYCN knockdown-mediated neuronal differentiation of MNA 
neuroblastoma cells. In paper III, two of the miRNAs positively correlated to MYCN 
expression (mir-92a and mir-92b) were shown to directly target the tumor suppressor DKK3 
(see chapter 6.4). 
We also observed several miRNAs being up-regulated upon MYCN knockdown in SK-N-
BE(2) cells, and most have previously been linked to a neuronal phenotype, or been shown to 
induce neuronal differentiation. Interestingly, let-7, a miRNA family reported to be involved 
in differentiation of neuroblastoma cells [180-182, 202], directly targets MYCN mRNAs, 
suggesting a feedback mechanism resulting in low N-myc levels during differentiation of 
MYCN-amplified cells (paper II, see below). The let-7 family of miRNAs is highly 
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represented in miRNA populations in mouse, rat and primate brains [204, 205]. Moreover, the 
expression of let-7, mir-218 and mir-137 has been reported to increase during induced 
neuronal differentiation in mouse embryonic stem cells, mouse and human embryonic 
carcinoma cells and mouse neuronal stem cells (mNSC) [206-208]. Additionally, the 
exogenous expression of mir-137 promoted neuronal-like differentiation in several mouse and 
human stem cells [207]. Very recently, mir-663 and mir-22 were reported to be up-regulated 
during ATRA-mediated differentiation of leukemic HL-60 cells [209]. In summary, these 
observations support the idea that miRNAs up-regulated during MYCN knockdown-mediated 
neuroblastoma differentiation are either directly involved in, or are a consequence of, the 
(neuronal) differentiation process. 
Notably, mir-21, a miRNA with established oncogenic functions in other cancers (reviewed in 
[210]), was found prominently up-regulated during MYCN knockdown (paper I) and 
neuroblastoma cell differentiation [180, 181, 202].  We found mir-21 expressed in all 
neuroblastoma cell lines investigated in this study and, interestingly, mir-21 expression was 
correlated to the MYCN mRNA expression in these cell lines. We cannot exclude that the 
expression of mir-21 is also influenced by variations in mir-21 gene dosages, as mir-21 is 
encoded on chromosome 17q which is frequently involved in unbalanced translocations in 
neuroblastoma cell lines [211]. However, an inverse correlation between MYCN and mir-21 
expression was also reported upon MYCN-induction in Tet21N cells [162] and primary 
neuroblastoma tumors [175]. Mir-21 is a miRNA with putative anti-apoptotic and tumor 
promoting activities, expressed in a variety of solid tumors. Experimentally validated mir-21 
targets include several proteins with tumor suppressor functions (reviewed in [210]). 
However, overexpression of mir-21 in SK-N-BE (2) and Kelly cells did not alter proliferation 
of these cell lines (paper I). In addition, mir-21 target genes remained unchanged (paper I). 
Similar to our study, Folini et al. recently reported that changes in mir-21 expression did not 
alter proliferation of prostate cancer cell lines [212]. Over-expression of mir-21 alone did not 
induce neuronal differentiation in SK-N-BE (2) or Kelly cells (paper I). Using antagomir-21 
to reduce mir-21 increase had no effect on differentiation (paper I). These observations 
indicate that the observed increase in mir-21 expression does not directly influence the 
neuronal differentiation process in MNA neuroblastoma cells induced to differentiate by 
MYCN knockdown. We suggest that the increase of mir-21 is a consequence rather than a 
cause for the differentiation process. We were not able to establish a clear function or a target 
for mir-21 in neuroblastoma cells (paper I). 
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In conclusion, paper I fits in a series of several published studies elucidating the effect of N-
myc on miRNA expression in neuroblastoma. The Supplementary tables give a current 
overview over miRNAs reported to be correlated with N-myc expression – both in primary 
tumors (Suppl. table 1) and cell lines (Suppl. table 2). 
6.3 The expression of N‐myc is regulated by miRNAs 
The interaction between N-myc and miRNAs is mutual, as MYCN itself is targeted by 
miRNAs. This is the main finding in paper II. Here, we aimed to investigate how miRNAs 
contribute to MYCN regulation. We systematically investigated the MYCN-3’UTR sequence 
for potential miRNA binding sites. We used luciferase reporter assays to show that the 3’UTR 
sequence is directly targeted by several miRNAs (mir-34a, -34c, -449, -19a, -19b, -29a, -29b, 
-29c, -101, -202 and let-7e). These miRNAs were further shown to decrease N-myc protein 
expression when overexpressed in the MNA neuroblastoma cell line Kelly. Finally, we 
showed that ectopic overexpression of let-7e, mir-101 and mir-202 efficiently inhibit 
proliferation and clonogenic cell growth in Kelly cells. 
It has been reported that certain mutations and SNPs in the 3’UTR of cancer-related genes 
increase cancer susceptibility and may allow the cancer cell to escape miRNA regulation 
[213]. In paper II, we showed that mutations in the MYCN 3’UTR are rare, both in MNA and 
non-MNA neuroblastoma cells, as we detected only a single SNP (rs922) at position 250 
(C250T) of the 3’UTR, which did not impair targeting of the MYCN-regulating miRNAs.  
The functionally best characterized MYCN-targeting miRNA is mir-34a, which is located at 
chromosome 1p36, a region frequently deleted in MNA neuroblastoma tumors [214]. 
Overexpression of mir-34a in MNA neuroblastoma cell lines decreased N-myc levels, 
inhibited proliferation and induced apoptosis. Interestingly, mir-34a is transcriptionally 
activated by p53 [155], implicating that deletion of mir-34a has similar cellular consequences 
as p53 deficiency [189]. In addition to MYCN, mir-34a targets BCL2 [188] and E2F3 [184], 
making mir-34a to a multi-faceted tumor suppressor miRNA in neuroblastoma. Mir-34b and -
34c are co-expressed from a locus at chromosome 11q23, another region commonly 
hemizygously deleted in neuroblastoma [108].  
In paper II, we confirm that mir-34a directly targets the 3’UTR sequence of MYCN. Whereas 
Wei et al. concluded that two mir-34 target sites were required to obtain maximum MYCN 
suppression by mir-34a, we found only one to be responsible for most of the suppressive 
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effect (2008). This result is supported by data from a study performed by Welch et al. [184]. 
We also verified that mir-34c and mir-449, but not mir-34b, target the MYCN 3’UTR similar 
to mir-34a. 
We confirmed, as earlier indicated by Lewis et al. [146], mir-101 as a MYCN-regulating 
miRNA and demonstrated its ability to suppress MYCN expression by binding to two 
predicted target sites. We further showed that mir-101 inhibits proliferation of MNA Kelly 
cells. These data from neuroblastoma extend previous reports showing tumor suppressor 
properties of mir-101 in different other cancer types [195, 215-219].  
Xu et al. have previously shown that mir-29 directly regulates B7-H3, a surface glycoprotein 
of the B7/CD28 family that is expressed on a wide variety of solid tumor cells, including 
neuroblastoma [220]. B7-H3 has immunoinhibitory effects protecting neuroblastoma cells 
from NK-mediated cytotoxicity [221]. In addition, B7-H3 is the target of the monoclonal 
antibody 8H9 [220] that showed promising results when used in compartmental 
radioimmunotherapy (cRIT) in a clinical trial for CNS-relapsed high-risk neuroblastoma 
([118], and chapter 2.1.6). Compared with normal tissue, mir-29 was found significantly 
lower expressed in neuroblastoma cells, contributing to a higher expression of B7-H3 on 
neuroblastoma cell surfaces [220]. It has been suggested that restoration of mir-29 and 
subsequent translational inhibition of B7-H3 might therefore prove therapeutically beneficial, 
both by sensitizing neuroblastoma cells to NK/T-cell-mediated immunotoxicity and by 
protecting B7-H3 expressing normal tissue from 8H9-related toxicity [220]. Our data from 
paper II extend the therapeutical potential of mir-29 as it was shown to directly target MYCN.  
The human let-7 miRNA family consists of 10 different mature let-7 sequences that are 
derived from 13 precursors [222]. Overexpression of let-7 has been shown to inhibit 
proliferation of several cancer cell lines [223-228]. Several important cell cycle regulators, 
including cyclins, cyclin-dependent kinases (CDKs), Ras, HMGA2 and c-Myc have 
previously been confirmed to be targets of let-7 [224-228]. The results from paper II have 
now added the MYCN oncogene to the list of cell cycle regulators targeted by let-7. The 
observed growth-inhibitory effect of let-7e on MNA neuroblastoma cells is most likely 
because of the combined suppression of several let-7 targets involved in cell proliferation. 
In summary, we were able to define a subset of miRNA that are able to regulate MYCN 
expression when overexpressed in MNA neuroblastoma cells. To what extent the N-myc 
protein is regulated by endogenous levels of these miRNAs, and if altered levels contribute to 
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neuroblastoma development, needs to be addressed in further studies. Recent data from 
miRNA profiling studies show that let-7e, mir-29a and mir-29c are significantly lower 
expressed in MNA primary tumors compared with non-MNA tumors [22], supporting the idea 
that they act as endogenous MYCN regulators. 
6.4 N‐myc‐regulated miRNAs target DKK3 
DKK3 is an established tumor suppressor gene that inhibits the proliferation of several 
cancers, including neuroblastoma. Koppen et al. demonstrated that in neuroblastic tumors 
arising from the sympathetic adrenal lineage, increased DKK3 mRNA levels are strong 
markers of differentiation: high DKK3 mRNA expression in differentiated ganglioneuromas 
and low DKK3 mRNA expression in undifferentiated neuroblastomas, correlating with poor 
prognosis [96]. It has also been shown that DKK3 mRNA levels are inversely correlated to 
MYCN mRNA expression in neuroblastic tumors and neuroblastoma cell lines [96, 97]. In 
paper III, we used two MNA neuroblastoma cell lines and induced MYCN-knockdown by 
retrovirally delivered anti-MYCN shRNA. For the first time, we were able to show that 
secretion of endogenous DKK3 protein into the cell culture media was increased upon 
MYCN-knockdown. Similar to the data presented by Koppen et al. [96] and Bell et al. [97], 
we also confirmed that DKK3 mRNA levels are inversely correlated to MYCN repression in 
neuroblastoma cell lines. Despite the well documented inverse correlation between MYCN 
and DKK3 expression, DKK3 does not seem to be transcriptionally down-regulated by N-myc 
promoter binding, as ChIP analysis failed to reveal a direct interaction between N-myc and 
the DKK3 promoter [96]. This suggests an indirect regulatory mechanism. 
To investigate if the DKK3 gene was inactivated by hypermethylation of the promoter region 
as reported from other cancers (see chapter 2.1.4.4), we analyzed the methylation status of the 
DKK3 promoter in 10 neuroblastoma primary tumors and five neuroblastoma cell lines using 
methylation-specific PCR (MSP). The results revealed that neither the primary tumors nor the 
cell lines were hypermethylated at the investigated CpG island of the DKK3 promoter. 
Therefore, we aimed to investigate if MYCN-regulated miRNAs contribute to DKK3 
regulation. In paper I, we demonstrated that mir-92a and -92b are positively correlated to N-
myc expression. The correlation between mir-92a and MYCN expression has also been 
confirmed in neuroblastic tumors [96]. Both mir-92a and mir-92b, in addition to let-7e, were 
predicted by in silico analyses to target the DKK3-3’UTR sequence.  In paper III, we were 
able to show that all three miRNAs efficiently decreased expression of a luciferase reporter 
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containing the 3’UTR sequence from DKK3. The predicted target seed sequence for mir-92a 
and mir-92b in the DKK3-3’UTR sequence was validated by mutagenesis. However, mutation 
of the putative let-7e seed sequences, separately or in combination, could not rescue the let-7e 
luciferase repression. This observation could be explained either by as yet unidentified and 
unpredicted let-7e seed sequences in the DKK3 3’UTR, other targets of let-7e indirectly 
influencing DKK3 expression, and/or off-target effects. By the use of miRNA mimics and 
antagomir treatment, we further demonstrated that both DKK3 mRNA expression and protein 
secretion into the media were inversely correlated to mir-92a, mir-92b and let-7e expression 
in neuroblastoma. 
Mir-92a is a member of the oncogenic mir-17-92 cluster that has been shown to be aberrantly 
expressed and to promote tumorigenicity in neuroblastoma (see chapter 2.3.2). With the 
exception of mir-92a, and to some extent mir-19a and -19b, none of the other mir-17-92 
members reduced expression of the DKK3 3’UTR luciferase reporter. We also reported a very 
robust inverse correlation between mir-92a and DKK3 expression in a series of 95 
neuroblastic tumors. 
DKK3 has been shown to be involved in tumor vessel biology and to be highly expressed in 
tumor endothelium [229]. DKK3 was reported to stimulate vascular growth and increase 
vascular density in tumors. We observed that the expression of the DKK3 protein in 
neuroblastoma vasculature was significantly higher in non-MNA tumors and benign 
ganglioneuroma in comparison to MNA tumors. This is in line with the previous report by 
Koppen et al. [96] demonstrating higher levels of DKK3 mRNA expression in both non-MNA 
neuroblastoma tumors and ganglioneuromas. However, the observation that a pro-angiogenic 
factor is down-regulated in high-stage tumors compared to lower stages is surprising. The 
mir-17-92 cluster has been related to angiogenesis [230]. Recently, it has been demonstrated 
that the in vivo inhibition of mir-92a enhanced blood vessel formation [231]. Our novel 
findings provide one possible explanation for this observation since DKK3 has been shown to 
stimulate angiogenesis [229]. The link between increased mir-92 expression in MNA 
neuroblastoma cells and reduced DKK3 expression in the endothelial cells in the tumor is 
unclear. 
It has been reported that miRNAs not only functions as intracellular regulators, but also as 
secreted effectors with paracrine and endocrine effects [232]. We therefore speculate that the 
tumor endothelial cells could be affected by mir-92 released from MNA tumor cells in 
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aggressive neuroblastomas. It should be investigated whether secreted MYCN-regulated 
miRNAs might be responsible for the low DKK3 expression in the endothelium of most 
aggressive tumors.  
Very recently, De Brouwer et al. published a study similar to paper III in this thesis, 
confirming mir-92a and mir-19 as a DKK3-regulating miRNA [233].  
7 Conclusions 
Neuroblastomas with MYCN-amplification are characterized by aggressive biology and poor 
survival of the patients. To improve future treatment options, it is of fundamental interest to 
understand MYCN’s role in tumorigenesis and determine factors regulating MYCN expression. 
In this thesis, we focused on the interactions between MYCN and miRNAs, a group of 
endogenous small regulatory RNA molecules that can act as both tumor suppressors and 
oncogenes.  
In paper I, we knocked-down MYCN in MNA cell lines by shRNA (appendix paper) and 
performed a miRNA expression profiling study to elucidate miRNAs that are correlated to 
MYCN expression. This approach is different from other studies used to investigate the role of 
N-myc on miRNAs, as MYCN knockdown in addition induces significant neuronal 
differentiation of the cells. We observed both up- and down-regulation of miRNAs. MiRNAs 
with positive correlation to MYCN included members of the oncogenic mir-17-92 cluster. One 
of the most prominently up-regulated miRNAs upon MYCN knockdown was mir-21. 
However, we were not able to establish a functional role for this miRNA during 
differentiation. 
Mir-92a and mir-92b were both positively correlated to MYCN expression. In paper III, we 
demonstrated that both miRNAs target the tumor suppressor DKK3 in neuroblastoma and 
repress secretion of the DKK3 protein.  
 
Finally, we demonstrated in paper II that the interaction between MYCN and miRNAs is 
mutual, as the MYCN mRNA itself is targeted by several miRNAs (paper II). Some of these 
miRNAs showed anti-proliferative properties. Re-establishment of these miRNAs in MYCN-
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Suppl. Table 1: Differentially expressed miRNAs between MNA and non-MNA primary tumors. 
U=up-regulated in MNA tumors. D=down-regulated in MNA tumors.












mir-17-5p U U U U U U U U
mir-18a U U U U U
mir-18a* U U U U
mir-19a U U U U U
mir-19b U U U















mir-30b D D D D
mir-30c D D D D
mir-30d D




mir-92 U U U U U U U
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mir-128a D D D D
mir-128b D
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mir-148a D D D
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mir-181a U U U U U U
mir-181a* U
mir-181a-2* U
mir-181b U U U
Mir-181d U U
mir-184 D D D
mir-186 D D
mir-189 D



























mir-330 D D D D
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mir-331-3p D D
mir-331 D D D D
mir-335 D D
mir-339-3p D















mir-488 D D D
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mir-539 D D D
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Suppl. Table 2: Correlation between miRNA and N-myc expression in neuroblastoma cell lines. 
pos=positive miRNA-N-myc correlation; neg=negative (invers) miRNA-N-myc correlation. 
MYCN=experimental MYCN change
*=binding to miRNA promoter confirmed by ChIP; (*)=binding to host gene promoter (ChIP); h vs l=high- 
MYCN state vs low-MYCN state 
Study 1 2 3a 3b 4 5 6a 6b 6c 7 8 9 10 11 12





let-7d pos pos neg
let-7f pos neg
mir-7 pos
mir-9 neg pos * pos*
mir-15b neg pos *
mir-17-5p pos pos pos* pos* pos pos* pos
mir-18a pos pos* pos* pos pos pos * pos* pos
mir-18a* pos pos *
mir-18b pos*
mir-19a pos pos* pos* pos pos pos * pos*
mir-19b pos
mir-20a pos pos* pos* pos pos pos * pos* pos
mir-20b pos pos no pos*
mir-21 neg neg














mir-92a pos pos pos* pos
mir-92 pos pos pos* pos* pos *
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6c=Mestdagh 2009 (ChIP on 6 cell lines); 7=Hu 2010 (LAN vs CHLA cell lines); 8=Loven 2010 (SHEP-
Tet21N); 9=Ma 2010 (SHEP-MYCN-ER); 10=Foley 2010 (SHEP-Tet21N); 11=Das 2010 (SHEP-Tet21N); 
12=Buechner 2010 (Kelly, shRNA)
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mir-610 neg neg (*)
mir-615 neg
mir-645
mir-660 pos
mir-663 neg
mir-671 neg
mir-768-3p neg
mir-801 pos
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